Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06948435

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hypertension Body Weight Cardiovascular Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Overweight or Obesity Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CEMEDIC, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • refer to the GZPL master protocol for screening eligibility.

Exclusion criteria

  • refer to the GZPL master protocol for screening eligibility.

Treatment and study plan

Orforglipron

Drug

Administered orally

Other names: LY3502970

Placebo

Drug

placebo administered.

Primary outcomes

  1. Change from Baseline in office Systolic Blood Pressure (SBP)

    Time frame: Baseline to Week 36

Secondary outcomes

  1. Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP

    Time frame: Baseline to Week 36

  2. Percent Change from Baseline in Body Weight

    Time frame: Baseline to Week 36

  3. Percent Change from Baseline in Triglycerides

    Time frame: Baseline to Week 36

  4. Percent Change from Baseline in non-HDL Cholesterol

    Time frame: Baseline to Week 36

  5. Percent Change from Baseline in hsCRP Concentration (mg/L)

    Time frame: Baseline to Week 48

  6. Change in office SBP in Randomized Withdrawal Population

    Time frame: Week 48 to Week 60

  7. Pharmacokinetics (PK): Steady-State Area Under the Concentration Curve (AUC) of Orforglipron

    Time frame: Baseline to Week 36

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 29, 2025
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.